Skip to main content
S&P 5007,591.70-0.58%DOW52,064.10-0.60%NASDAQ26,081.72-0.65%BTC$76,799.00-1.71%ETH$2,453.65-0.48%GOLD$4,367.20-0.91%OIL$103.26+0.76%
Smart Investors Daily
AS

NASDAQ · ASND

Ascendis Pharma A/S

Healthcare · Biotechnology

$261.23

Up+$0.42 (+0.16%)

Updated Sep 11, 2026, 8:36 AM

SID Score

6.0/10

Composite research score

Smart Money

58/100

Neutral

Market cap
14.33B
P/E ratio
-53.27
Dividend yield
0.00%
52-week range
$203.80 – $282.15
Volume
505.04K
Avg. volume
711.81K

Price performance

ASND price history

1M range · 20 trading sessions · Daily adjusted prices

ASND closed at $261.23 after 20 trading sessions, up 6.09% for the selected period.

Last close
$261.23
Period change
+6.09%
Period low
$246.23
Period high
$271.12
Daily close
View OHLC price history
ASND OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 10, 2026$260.00$262.17$258.01$261.23505.04K
Sep 9, 2026$270.89$272.3703$260.75$260.81497.43K
Sep 8, 2026$263.41$272.4665$262.32$270.09653.37K
Sep 4, 2026$267.96$271.14$265.22$270.56723.52K
Sep 3, 2026$266.94$272.44$265.80$271.121.02M
Sep 2, 2026$261.39$268.71$257.52$267.31418.3K
Sep 1, 2026$261.65$266.6301$256.275$260.25610.6K
Aug 31, 2026$247.65$268.98$247.65$263.041.03M
Aug 28, 2026$248.11$250.23$246.30$247.91314.79K
Aug 27, 2026$249.73$250.69$248.41$249.36189.54K
Aug 26, 2026$252.84$252.84$249.16$250.25237.43K
Aug 25, 2026$253.01$256.60$251.325$252.99333.52K
Aug 24, 2026$256.35$256.35$247.0276$251.95329.92K
Aug 21, 2026$253.62$257.885$252.87$253.29363.77K
Aug 20, 2026$256.65$260.98$253.21$254.81533.64K
Aug 19, 2026$255.00$261.61$251.11$259.62541.22K
Aug 18, 2026$246.47$253.55$245.68$248.85452.63K
Aug 17, 2026$246.33$250.6184$242.00$247.40607.65K
Aug 14, 2026$243.63$249.52$240.64$248.50650.36K
Aug 13, 2026$250.38$251.43$244.12$246.231.06M

Latest ASND news

The latest Smart Investors Daily articles mentioning ASND.

Stock researchCompany · Overview

ASND research

Overview

Company profile and research snapshot.

Company profile

Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$246.67
Implied upside
—
Analysts
—
ASND recent ratings
DateFirmRatingTarget
Sep 2, 2026OppenheimerOutperform—
Sep 1, 2026WedbushOutperform—
Sep 1, 2026Morgan StanleyOverweight—
Aug 31, 2026HC Wainwright & Co.Buy—
Aug 31, 2026StifelBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 4, 2026

Ascendis Pharma (ASND) Reimbursement Win Puts Its Fair Value Narrative Back In Focus

Ascendis Pharma (NasdaqGS:ASND) drew fresh investor attention after Canada’s Drug Agency recommended conditional public reimbursement for Yorvipath, its parathyroid hormone replacement therapy for eligible adults with chronic hypoparathyroidism. Ascendis Pharma’s recent news flow, including the Canadian reimbursement recommendation for Yorvipath and the late August global settlement with BioMarin over Yuviwel, has arrived alongside strong price momentum, with a 90 day share price return of...

Yahoo · Sep 1, 2026

Eyconis to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

REDWOOD CITY, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Eyconis, Inc., a clinical-stage biotechnology company advancing next-generation, long-acting ophthalmic therapeutics, today announced that members of its management team will participate in one-on-one investor meetings at the Morgan Stanley 24th Annual Global Healthcare Conference, taking place September 14–16, 2026, in New York City. Eyconis @ Morgan Stanley 24th Annual Global Healthcare ConferenceDate: September 16, 2026Location: New Yor

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By